MBX Biosciences, Inc. (MBX)
NASDAQ: MBX · Real-Time Price · USD
28.00
+0.05 (0.18%)
Mar 13, 2026, 4:00 PM EDT - Market closed

MBX Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
18.910.786.783.76
Research & Development
79.1657.4228.5321.4
Total Operating Expenses
98.0668.1935.3125.16
Operating Income
-98.06-68.19-35.31-25.16
Total Non-Operating Income (Expense)
11.086.272.75-0.97
Pretax Income
-86.97-61.92-32.56-26.14
Net Income
-86.97-61.92-32.56-26.14
Net Income to Common
-86.97-61.92-32.56-26.14
Shares Outstanding (Basic)
371111
Shares Outstanding (Diluted)
371111
Shares Change (YoY)
243.01%944.70%52.73%-
EPS (Basic)
-2.38-5.82-31.96-39.18
EPS (Diluted)
-2.38-5.82-31.96-39.18
Free Cash Flow
-81.88-55.56-32.11-23.56
Free Cash Flow Per Share
-2.24-5.22-31.52-35.33
EBITDA
-97.81-67.95-35.15-25.11
EBIT
-98.06-68.19-35.31-25.16
Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q